Donepezil (Aricept) CADASIL Study 

We were honored in recruiting patients for this study. Potential patients are notified directly by us.  It will be their decision to contact the study. Coordinator if they are interesting in participating in the study. No personal information was shared as we respect your privacy.

The study opened January 2006
Closed July 2006

Results Of This Study

This was a randomized trial of Donepezil (Aricept, Eisai/Pfizer) in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). 

Thank you to everyone who was screened and participated in the study. Over 255 patients were screened worldwide to participate in the study; approximately 168 patients  have completed the study. We want to personally want to thank the Eisai and Parexel Companies,  the doctors as well as the researchers for their dedication and hard work.

Dr. Edwin H. Kolodny, New York
Dr. Gregory Pastores, New York
Dr. Jose Biller, Loyola University Maywood, Illinois 
Dr. James W. Schmidely, University of Arkansas
Dr. Michael Geschwind, San Francisco, California
Dr. Stephen Salloway, Providence, Rhode Island
Dr. Michael D. Hill, Alberta, Calgary , Canada
Dr. Antonio Federico, Siena, Italy
Dr. Keith Muir, Glasgow, Scotland, UK
Dr. Hugh Markus, London, England
Dr. Martin Dichgans, Marchionistrasse München Germany